04/26/2018
RICHLAND, Wash., April 26, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical ...
04/18/2018
RICHLAND, Wash, April 18, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company ...
02/08/2018
Fourth Consecutive Quarter of Year-Over-Year Revenue Increases RICHLAND, Wash., Feb. 08, 2018 (GLOBE NEWSWIRE) ...
02/08/2018
Study Demonstrates “Resection Cavity Contractions Affects Cs-131 Dose Distribution Significantly Less than that of ...
01/31/2018
RICHLAND, Jan. 31, 2018 (GLOBE NEWSWIRE) -- - IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical ...
01/24/2018
Revenue Increase Driven by Increasing Traction of New Sales Strategies in Prostate Brachytherapy
RICHLAND, Wash, ...
01/09/2018
Possible Evidence of Paradigm Shift in the Radiation Treatment of Cancers Afflicting the Brain
RICHLAND, Wash.,, ...
01/08/2018
10 Year Exclusive Agreement to Supply Proprietary Cesium-131 Seeds Embedded in Collagen Tiles
RICHLAND, Wash., ...
11/14/2017
Revenue of $1.21 Million, 12% First Quarter-Over-First Quarter Increase, Gross Margin of 22% RICHLAND, Wash., ...
11/09/2017
Potential New Application for Cesium-131 for Unmet Medical Need
RICHLAND, Wash., Nov. 09, 2017 (GLOBE NEWSWIRE) --
09/28/2017
Gross Margin Expands to 36% on Continued Process Improvements and Expense Reduction
RICHLAND, Wash., Sept. 28, ...
09/26/2017
Study Demonstrates Ability to Control Local Disease Over Reasonably Long Period of Time, A Major Step in Preserving
[dsm_card title=”Media & Public Relations Contact” button_url_new_window=”1″ _builder_version=”4.8.1″ _module_preset=”default” background_color=”#FFFFFF” custom_margin=”||0px||false|false” hover_enabled=”0″ sticky_enabled=”0″]
If you have questions or need help, please contact:
Chuck Padala
Public and Media Relations
[/dsm_card]